TrialThe Journal of infectious diseases2025

Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.

Nithya Thambi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.